RT Journal Article
T1 Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
A1 Novillo Villajos, Apolonia
A1 Gaibar, María
A1 Romero Lorca, Alicia
A1 Gilsanz, María Fuencisla
A1 Beltrán, Laura
A1 Galán, Miguel
A1 Antón, Beatriz
A1 Malón, Diego
A1 Moreno, Amalia
A1 Fernández Santander, Ana
AB Background: In metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves progression-free survival compared to chemotherapy (CT) alone. This benefit is not, however, observed in all patients. While increased chemokine CXCL5 gene expression promoting angiogenesis has been proposed as a prognostic mCRC biomarker, few studies have examined its relationship with drug efficacy. This study sought to analyze tumor CXCL5 gene expression in six patients with different efficacy of BVZ-containing CT in terms of the tumor response to treatment.Case summary: We report six cases of stage IV KRAS-mutated mCRC. Patients were given first line treatment with BVZ-containing chemotherapy in University Hospital of Fuenlabrada. The six patients differed in terms of primary tumor location (right/left side), tumor burden (mostly hepatic and peritoneal disease) and clinical disease course. Before treatment onset, total RNA was isolated from paraffinated tumor biopsy specimens and CXCL5 gene expression quantified through conventional RT-qPCR procedures. Our main finding was that CXCL5 expression levels were several times higher in three patients with lower progression free survival (under 6 mo) from the start of treatment.Conclusion: A higher expression of CXCL5 was observed in the three patients showing worse tumor response to treatment.
PB Baishideng Publishing Group
SN 1007-9327
YR 2020
FD 2020-04-28
LK https://hdl.handle.net/20.500.14352/130301
UL https://hdl.handle.net/20.500.14352/130301
LA eng
NO Novillo, A., Gaibar, M., Romero-Lorca, A., Gilsanz, M. F., Beltrán, L., Galán, M., Antón, B., Malón, D., Moreno, A., & Fernández-Santander, A. (2020). Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports. World journal of gastroenterology, 26(16), 1979–1986.
NO Universidad Europea de Madrid
NO Fundacioón de la Universidad Europea de Madrid
DS Docta Complutense
RD 1 abr 2026